Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

The following table reflects the calculation of basic and diluted loss per common share (in thousands, except per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025


Net loss per ImmunityBio common share – basic and diluted
Numerator:
Net loss attributable to ImmunityBio common stockholders	$	(230,378)	$	(92,555)	$	(863,160)	$	(222,201)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted	1,050,070		888,216		1,038,536		870,786
Net loss per ImmunityBio common share – basic and diluted	$	(0.22)	$	(0.10)	$	(0.83)	$	(0.26)

Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted net loss per share. The following table details the number of shares of common stock underlying those securities that were excluded from the computation of weighted-average number of common shares outstanding – diluted (shares in thousands):


	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025


Related-party convertible note	88,447	93,053	88,447	93,053
Outstanding third-party warrants	47,862	35,424	47,862	35,424
Outstanding stock options	23,559	25,931	23,559	25,931
Outstanding RSUs	5,931	9,055	5,931	9,055
Outstanding related-party warrants	1,638	1,638	1,638	1,638
Total	167,437	165,101	167,437	165,101

The potentially dilutive securities shown in the table above exclude an option to purchase up to approximately $5.0 million of the company’s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price cannot be determined until the date of exercise. See Note 10 “Revenue Interest Purchase Agreement” for more information.